MIRAMAR, FL /ACCESSWIRE/November 14, 2022/ Stemtech Corporation (“Stemtech”) (OTCQB: STEK), an innovative stemceutical™ company and pioneer in the field of stem cell nutrition, today announced the release of an enhanced version of its Stemtech AdvanceOffice mobile application.
Stemtech Corporation President and Chief Operating Officer John W. Meyer announced that “Stemtech continues to make progress in providing industry-leading technology to our Independent Business Partners (IBPs). September 19e2022, we were excited to launch and commission our powerful Stemtech Advance Office mobile app business tool as part of our commitment to provide the best tools for our freelance sales domain. This improves our sales process and makes our IBP relationship management much more efficient. It allows them to focus on what they do best.”
Sandra Kazickaite, VP of Stemtech Global Performance, who spearheaded the launch of AdvanceOffice, said, “Stemtech strives to deliver innovation every day. While continually expanding our market coverage, we aim to provide the best tools available. One of the exciting things we offer our IBP community is ADVANCEOFFICE, our new mobile app. It’s a tool that allows our IBPs to take their Stemtech business to the next level and achieve success by promoting all-natural products at herbal, anti-aging and longevity, the extraordinary health and inbound earning opportunity in wellness – all from a mobile device!”
Sandra continued “In early December 2022, we will be adding new essential features to our AdvanceOffice mobile app. Our recent app development efforts have enabled Stemtech to offer business analytics reports. These in-app reports will provide our IBPs an instant view of key performance indicators for their business. Through integration with CRM Back Office software, we will soon be able to easily view this vital business data within the application. The combination of activity reports with The mobile app’s prospecting functionality is intended to generate powerful business development and communication efforts with ease.”
About Stemtech Corporation
Stemtech Corporation, a leading stemceutical™ company with a direct sales distribution model, was founded on April 18, 2018, after acquiring the business of its predecessor Stemtech International, Inc., which was founded in 2005. From 2010 to 2015, Stemtech International, Inc., was recognized on the Inc. 5000 Fastest-Growing Companies list four times. In 2018, Stemtech underwent an extensive management reorganization and continued operations under new management as Stemtech Corporation. In August 2021, Stemtech became a publicly traded company (OTCQB: STEK) and expanded business opportunities for its independent business partners, who can earn revenue by sharing Stemtech products. January 2022 marked the introduction of new marketing efforts. In August 2022, Professor Doctor Bankole Johnson joined Dr. Enrique Martinez and Dr. Lizette Leos on Stemtech’s Life Sciences Advisory Board. In September 2022, the new Stemtech AdvanceOffice mobile application based on the VERB Technology platform was successfully launched as a powerful communication and recruitment tool for our field. On November 1, 2022, Stemtech introduced the new OraStem travel/sample size® Toothpaste. In October, Life Factor Research became the Research and Development, Product Formulation – Science division of Stemtech to create stem products, skin care and other cutting-edge products. In December, Stemtech will showcase a new skincare product at the Cancun Leadership Conference.
This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements identified by words such as “believes ‘, ‘expects’, ‘plans’, ‘estimates’, ‘intends’, ‘plans’, ‘target’, ‘projects’ and similar expressions. The statements in this release are based on the current beliefs and expectations of the management of our company and are subject to significant risks and uncertainties. Actual results may differ from those set forth in forward-looking statements. Many factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, challenges inherent in new product development initiatives, the effect any competing products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is needed to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any government review of our products or practices, and other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our last 10-Q report filed August 23, 2022. We undertake no obligation to update any forward-looking statement or information contained in this press release. itself or in other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Stemtech Corporation that are tolerated by the Company must come from the Company itself and bear our name as the source.
THE SOURCE: Stemtech Corporation